TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.
TD Cowen analyst Tara Bancroft maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and raises the price target from $155 to $160.